

#### **MEDICAL PRESCRIPTION FORM**

CONSULTATION CERTIFICATE / CERTIFICAT OF INFORMATION AND CONSENT FOR TESTING



Customer relation service Tel.: +33 (0)1 34 40 97 76 Fax: +33 (0)1 34 40 21 29

Email: intgb@lab-cerba.com

Laboratoire Cerba

## PRENATAL GENETIC, INFECTIOUS AND BIOCHEMICAL DIAGNOSIS

Mandatory completion of the signed consultation certificate and consent form (page 3)

TESTING LABORATORY								
Customer n°: LLLLC/L								
Mandatory stamp								
Mandatory stamp								
PATIENT	Prescriber							
SURNAME	SURNAME							
FIRST NAME	FIRST NAME							
Maiden name	Address							
Address	CP City							
CP City								
Date of birth:	Fax LIILILILI							
	E-mail address:							
PARTNER:								
Surname: First name:	Date of birth:							
SAMF	PLING							
Sampling date:	Term: W.A							
CURRENT PREGNANCY:	TERMINATED PREGNANCY:							
☐ Amniotic fluid	☐ Placenta ☐ Cord							
☐ Fetal blood	☐ Chorion ☐ Other (specify):							
☐ Chorionic villus (It is imperative that the sample is taken on the day of despatch in a transport medium available on request.)								
CURRENT PREGNANCY:								
■ LMP: ■ GA:	☐ Singleton pregnancy ☐ Twin pregnancy							
■ 1st trimester ultrasound Date:	CRL: mm Nuchal translucency: mm							
Is this a 2nd puncture								
Number of foetuses sampled: ☐ 1: volume ml/mg appear	rance:							
☐ 2: Identifier of fetus no. 1= D1: volume	ml/mg appearance:							
: Identifier of fetus no. 2= D2: volume	ml/mg appearance:							
	HISTORY OF THE PATIENT							
	me partner Different partner							
2								
<b>S</b>								
Child with a genetic or chromosomal abnormality:								
MEDICA	L HISTORY							
Maternal side	Paternal side							
■ Child with a genetic or chromosomal								
abnormality (description):								
Genetic disease (which) :								



### **M**EDICAL PRESCRIPTION FORM

# PRENATAL GENETIC, INFECTIOUS AND BIOCHEMICAL DIAGNOSIS



Customer relation service Tel.: +33 (0)1 34 40 97 76 Fax: +33 (0)1 34 40 21 29

Laboratoire Cerba

Email: intgb@lab-cerba.com

Mandatory completion of the signed consultation certificate and consent form (page 3)

CY	IOGENETICS, MOL	ECULAR CYTOG	ENETICS AND MOLEC	SULAR GENETICS			
INDICATION:							
☐ cfDNA positive screening <sup>5</sup>			(3A) History of preg	nancy with abnormal karyotype for the couple <sup>2</sup>			
☐ (4A) Trisomy 21 ☐ (4B) Tri	somy 18		☐ (6A) Maternal age ≥	2 38 years where screening for trisomy 21 could not			
( )	hers:		be performed				
(4E) cfDNA screening not usable o			(8A) Convenience				
(2A) Parental chromosomal abnorn	•		☐ (7C) Sampling for in	nfectious disease			
☐ (5B) Ultrasound anomalies¹ (outside CN ≥ 3.5mm)			☐ (7D) Sampling for genetic disease				
☐ (5A) Nuchal translucency ≥ 3.5mm <sup>1</sup>			☐ (3A) Investigation of a known fetal chromosomal abnormality				
☐ Maternal serum markers³			(7B) Other (Specify):				
☐ (1B) MSM 1 <sup>st</sup> T ☐ (1D) MS Result: 1 /	SM 2 <sup>nd</sup> T alone		(7B) Other (Specify)	<i>/</i>			
PRESCRIPTION:							
☐ Fetal karyotype (Amniotic fluid: 09601; Fetal	blood: 09708 ; Chorionic villus: 0	09901)					
☐ Chromosomal analysis by DNA chi	p (ACPA) (PPREN)						
☐ DNA conservation							
☐ Test for micro-deletion syndrome (c	9984):	schhorn (4p-)	☐ Di-George (22q11	)			
□ Rapid diagnosis of aneuploidy (FISH) on indication: ultrasound warning sign or on positive cfDNA test for T21 or not usable on a 2 <sup>nd</sup> sample <sup>5</sup> or MSM ≥ 1/50 (TLA)							
□ Rapid diagnosis of trisomies13,18 positive for T13 or T18 (TLA)	3 and 21 by PCR fo	or indications othe	r than the ultrasound	anomalies (non-covered) or MSM < 1/50 or cfDNA			
$\square$ Test for uniparental disomy of the $\sigma$	chromosome <sup>4</sup> (DUP) (s	pecify):					
☐ Determination of zygosity (43902)							
☐ Achondroplasia <sup>4</sup> (43401)	☐ Hypochondropla	asia <sup>4</sup> (44401)	☐ Apert Syndrome <sup>4</sup>	(APERT)			
☐ Study of the SHOX gene <sup>4</sup> (SHOXM)	☐ Mucoviscidose <sup>4</sup>	(CFSEQ)	☐ Steinert's myotonic dystrophy <sup>4*</sup> (DM1)				
☐ Spinal muscular atrophy <sup>4</sup> (SMA)	☐ Rett Syndrome <sup>4</sup>	(MECP2)	☐ Prader-Willi Synd	rome <sup>4</sup> (PWSME)			
☐ Sickle cell anaemia⁴ (DREP)	□ Beta thalassemi	а <sup>4</sup> (нвета)					
☐ Gene panel - Exome (NGS) (EXOCY)	see online catalogu	e: https://www.lab-ce	rba.com/files/live/sites/Cer	ba/files/documents/EN/FDE Exome EN.pdf			
☐ Other (specify):							
	Di	AGNOSIS OF INF	ECTIOUS DISEASES				
PRESCRIPTION:							
☐ Cytomegalovirus (CMV) by PCR (CM	PCR)	☐ Toxoplasma g	ondii par PCR (TGPCR)	☐ Parvovirus B19 by PCR (19PCR)			
☐ Varicella-zoster (VZV) by PCR (VZPC	R)	☐ Enterovirus by	RT-PCR (ENTPT)	☐ Herpes virus 1 and 2 (HSV) by PCR (HSPCR)			
☐ Rubella by RT-PCR*(RUBAM) (manda	tory freezing)	☐ Zika by RT-PCR (ZIKAP)					
☐ Other (specify):							
INDICATION:							
☐ Ultrasound anomalies¹							
☐ Hypotrophy/ isolated intrauterine	growth restriction	☐ Cereb	ral ventricular dilatatio	n Hyperechogenic bowel			
☐ Hydramnios ☐ Intrauterine fetal demise ☐ Other (specify):							
☐ Maternal seroconversion <sup>6</sup>							
	2 <sup>nd</sup> Trimester	_	☐ 3 <sup>rd</sup> Trimester	☐ Undated			
☐ Clinical maternal varicella infection		☐ Other (speci	fy):				
	FE	TAL BIOCHEMIS	TRY (amniotic fluid)				
PRESCRIPTION:							
☐ Alpha-fetoprotein (22207) ☐ A	cetylcholinesterase (	70106) Digest	ive enzymes* (ENZDI)	☐ Other (specify):			
INDICATION:							
Maternal serum AFP ≥ 2.5 MoM		☐ Ultrasound sig	ns suggesting a NTD1	☐ Other ultrasound anomalies¹			
☐ Maternal treatment (particularly De	pakine®)	☐ History of failu	re of neural tube closur	e			
Systematic analysis		☐ History of nep	nrotic syndrome				
Documents to be enclosed:							
¹The ultrasound report			blood samples				
<sup>2</sup> the cytogenetics result	21 rick		A test report ogy test results	* toot cont			
3the report of the calculation of fetal T	LI IION	uie sero	ogy test results	* test sent			



### CONSULTATION CERTIFICAT FROM THE PRESCRIBER CERTIFICAT OF INFORMATION AND CONSENT PATIENT FOR TESTING



#### Laboratoire Cerba Customer relation service Tel.: +33 (0)1 34 40 97 76

Fax: +33 (0)1 34 40 21 29 Email: intgb@lab-cerba.com

### PRENATAL GENETIC, INFECTIOUS AND BIOCHEMICAL DIAGNOSIS

Mandatory completion of the signed consultation certificate and consent form (document below)

CONSULTATION CERTIFICATE FROM THE PRESCRIBING PHYSICIAN OR THE GENETIC COUNSELOR									
☐ POSTNATAL DIAGNOSIS									
I, the undersigned, Dr./Prof	I, the undersigned, Dr./Prof								
certify that I have informed the undersigned patient and his/her parents (legal representatives) about the characteristics of the investigated disease, how to diagnose it, how to prevent and treat it, how the disease is transmitted and the possible consequences in other members of the family, the storage of the sample, and that I have obtained the consent of the patient AND his/her guardianship under the conditions provided for by the French public health code (articles R113-4 and 5).									
☐ PRENATAL DIAGNOSIS									
I, the undersigned, Dr./Prof	or	genetic cour	nselor under the supervision	on of Dr./Prof					
I, the undersigned, Dr./Prof genetic counselor under the supervision of Dr./Prof genetic counselor under the supervision of Dr./Prof genetic counselor under the supervision of Dr./Prof genetic or infectious abnormality, the characteristics of this disease, how to detect it, the associated risk and the possible consequences of an abnormal outcome.									
CONSENT OF THE PREGNANT WOMA		Consent for gen	ETIC TESTING OF A PE	RSON					
TESTING FOR AN <i>IN UTERO</i> Decree of January 14, 2014, con									
I, the undersigned, Mrs		certify that I have received:							
Information on the risk to the unborn child disease, the characteristics of this disease of fetal medicine, treatment or management	e; how to diagnose it; the potential options	Information on the genetic test that is offered to me, that will be per (check below):							
,	y to allow making an in utero prenatal diagnosis								
that have been offered to me and that I require the collection of a sample of am	the biosample(s) taken from my child or from the adult under guardianship								
blood or any other fetal sample; the proce	edures, risks, disadvantages and possible	the sample that will be taken	from my dead fetus						
consequences of each sampling technique have been explained to me; I have been	informed that a second sample may be	<ul> <li>Information on the genetic tests the</li> <li>confirm or rule out the diag</li> </ul>		ease related	to my				
required in case of technical failure; if this consent; other diseases than that or thos		symptoms;			•				
by the test; I have been informed that the and explained to me by the physician who		<ul><li>confirm or rule out the presym</li><li>identify a healthy carrier sta</li></ul>							
I consent to the collection (required for testin		chromosomal rearrangement)  assess my genetic susceptibil		eatment.					
amniotic fluid chorionic	· · · ·	assess my genetic susceptibility to a disease or drug treatment.  I have been informed:							
☐ fetal blood ☐ other fetal	sample (specify)	- Of my right to request the interruption of this study, that the results are not							
I also consent to the test(s) (*) for which this sample is taken:									
<ul> <li>cytogenetic testing, including molecular tests applied to cytogenetics;</li> <li>That the full interpretation of these results is based, in sor definition of biological relationships, which can be analyzed</li> </ul>									
□ molecular genetic testing;  - Of my responsibility regarding my duty to inform my family,									
fetal chemistry diagnostic tests;  abnormality is revealed, the consequences of which are likely to result in									
□ laboratory tests for the diagnosis of infectious diseases. implementation preventive measures, including genetic counseling or care.									
I authorize the storage of a biosample taken to me and its subsequent use to <b>continue investigations</b> as <b>part of the same diagnostic process</b> , depending on the evolution of knowledge.					□ No				
The technique used may reveal genetic information that is unrelated to the investigated disease, but that may have an impact on my health or that of relatives. I would like to be informed of these results.					□ No				
I authorize the transmission of a sample along with the necessary medical data, including any photographs, to another laboratory to complete this					□ No				
genetic study. I authorize the recording and storage of medical data useful for the management of the diagnostic process in computer databases					□ NI=				
I authorize the <b>recording and storage of medical data</b> useful for the management of the diagnostic process in computer databases					□ No				
As part of the diagnostic process, part of my sample may not be used. I authorize its storage and use for internal laboratory quality assurance studies.					□ No				
I authorize the anonymized use of medical data and/or part of the samples within the framework of research projects, of a scientific study program without direct benefit or loss to me (all my medical data will be protected through total anonymization).					□ No				
		:-:		- <b>f</b> l	- ! 41				
The result of this test will be available to me a context of a genetic consultation. This or these									
of this document will be kept in my medical re	• • • • • • • • • • • • • • • • • • • •	·			٠,				
aboratory in which the practitioner who performed the tests works will keep this document under the same conditions as the test report. I have had the opportunity to ask questions to the geneticist or genetic counselor who prescribed this test and all my questions have been answered satisfactorily.									
Done in									
PATIENT IDENTITY (Signature)	IDENTITY of the LEGAL REPRE	IDENTITY of the LEGAL REPRESENTATIVE(S) (Signature)  PRESCRIBER							
Last name:	Last name, first name, date of birth:  Last name:								
First name:	Last name, first name, date of birth:	ame, first name, date of birth:							
Date of Birth:	If the patient is minor or an adult under guardian	ship, relationship to the patient:							